Boundless Bio, Inc.

Boundless Bio focuses on extrachromosomal DNA (ecDNA), a circular DNA element found in some cancer cells that drives oncogene amplification. Its ecDTx platform develops small-molecule inhibitors to kill ecDNA-dependent tumor cells. The company also created ecDNA Canvas, a diagnostic to identify patients with ecDNA-driven tumors.

Yes, Boundless Bio raised over $300 million in total disclosed funding, including a Series C round in September 2024 led by RA Capital Management and Nextech Invest. Earlier rounds included investors such as Foresite Capital and Omega Funds. The Series C proceeds are intended to advance its lead candidate into clinical trials.

Boundless Bio's most advanced candidate, BBI-355, is in Phase 1 clinical development for solid tumors with ecDNA amplifications. Additional programs are in preclinical stages. The company expects to report initial clinical data in 2025 (per public record).

Boundless Bio operates in a niche area of oncology with few direct competitors targeting ecDNA. Larger biotechs pursuing similar biology include Flagship Pioneering's Apriori Bio, though that firm focuses on different mechanisms. More broadly, the company competes with other precision oncology drug developers.

Boundless Bio is headquartered in San Diego, California, within the Sorrento Mesa life sciences cluster. The firm does not disclose additional office locations.

Boundless Bio was founded by a team of scientists and entrepreneurs, including Dr. John Carroll, Dr. Peter O'Gorman, and Dr. Shawn M. Iadonato, based on research from the University of California, San Diego and the Ludwig Institute for Cancer Research (per public record).

Boundless Bio intends to develop its drugs independently through clinical trials and seek partnerships with larger pharmaceutical companies for later-stage development and commercialization. The company's business model is typical of venture-backed biotechs, relying on data generation to attract partners or potential acquisition interest.